Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

Company Overview

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological conditions. The company’s research and development activities are centered on therapies intended to address significant unmet needs in inflammatory skin diseases.

Arcutis’s primary commercial product is ZORYVE (roflumilast), a topical, nonsteroidal phosphodiesterase-4 inhibitor. The product is available in multiple formulations and strengths for certain patients with plaque psoriasis, seborrheic dermatitis and atopic dermatitis. ZORYVE is designed for application to affected skin and is intended to provide an alternative to some existing topical treatment approaches.

The company was founded in 2016 and is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. dermatology market and continues to pursue additional regulatory approvals and uses for its dermatology portfolio. Frank Watanabe serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $25.80 to $27.09
• 50-Day Range: $23.38 to $28.42
• 52-Week Range: $16.71 to $31.77
• Volume: 2.04 million shs
• Average Volume: 3.23 million shs
• Market Capitalization: $3.38 billion
• P/E Ratio: 128.20
• Dividend Yield: N/A
• Price Target: $35.57
• Consensus Rating: Moderate Buy

Arcutis Biotherapeutics Stock Analysis - MarketRank™

Arcutis Biotherapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 140th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Arcutis Biotherapeutics has a consensus price target of $35.57, representing about 32.1% upside from its current price of $26.92.

Amount of Analyst Coverage

Arcutis Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 171.43%

Earnings Growth

Earnings for Arcutis Biotherapeutics are expected to grow by 171.43% in the coming year, from $0.42 to $1.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcutis Biotherapeutics is 128.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcutis Biotherapeutics is 128.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.41.

Price to Book Value per Share Ratio

Arcutis Biotherapeutics has a P/B Ratio of 17.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.21% of the float of Arcutis Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.54.

Change versus previous month

Short interest in Arcutis Biotherapeutics has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcutis Biotherapeutics does not currently pay a dividend.

Dividend Growth

Arcutis Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.88

News Sentiment

Arcutis Biotherapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.

Search Interest

10 people have searched for ARQT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,015,966.00 in company stock.

Percentage Held by Insiders

9.40% of the stock of Arcutis Biotherapeutics is held by insiders.

Percentage Held by Institutions

Arcutis Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ARQT
• CIK: 1787306
• Web: www.arcutis.com
• Phone: 805-418-5006
• Fax: N/A
• Employees: 354
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Arcutis Biotherapeutics: $35.57
• High Price Target: $40.00
• Low Price Target: $29.00
• Potential Upside/Downside: +32.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: 128.20
• Forward P/E Ratio: 64.10
• P/E Growth: N/A
• Net Income: -$16.14 million
• Net Margins: 6.15%
• Pretax Margin: 6.31%
• Return on Equity: 15.05%
• Return on Assets: 6.51%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 2.92
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $376.07 million
• Price / Sales: 9.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.55 per share
• Price / Book: 17.37

Miscellaneous

• Outstanding Shares: 125,690,000
• Free Float: 113,877,000
• Market Cap: $3.38 billion
• Optionable: Optionable
• Beta: 1.50